Kelun Pharmaceutical adds five drugs to national medical insurance list

Sichuan Kelun Pharmaceutical announced on December 7, 2025, that five of its drug products, including those from its subsidiaries, have been added to the National Medical Insurance Drug Catalog (2025 Edition). This inclusion is set to take effect from January 1, 2026, with the protocol valid until December 31, 2027. The drugs include injectable formulations such as Meropenem/Sodium Chloride Injection, Imipenem and Cilastatin Sodium/Sodium Chloride Injection, Aconosumab for Injection, Cetuximab Injection, and Tagrisso Injection, all confirmed as proprietary products.

Sales of these drugs amounted to approximately 51.69 million yuan in 2024. For the first half of 2025, their combined sales reached approximately 309.75 million yuan, representing 0.24% and 3.41% of the company's total operating revenue during the respective periods.

The company anticipates that this inclusion will enhance market penetration and sales volume, though the precise impact on its operating performance cannot yet be estimated. Further details regarding medical insurance payment standards and reimbursement rules will be released by relevant government departments.